Dermata Therapeutics, Inc.
DRMA
$0.8721
-$0.0358-3.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.31M | 4.39M | 4.47M | 4.49M | 3.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.51M | 11.53M | 10.12M | 8.97M | 8.04M |
| Operating Income | -12.51M | -11.53M | -10.12M | -8.97M | -8.04M |
| Income Before Tax | -12.29M | -11.27M | -9.82M | -8.69M | -7.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.29 | -11.27 | -9.82 | -8.69 | -7.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.29M | -11.27M | -9.82M | -8.69M | -7.79M |
| EBIT | -12.51M | -11.53M | -10.12M | -8.97M | -8.04M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -14.20 | -19.96 | -26.01 | -31.26 | -58.29 |
| Normalized Basic EPS | -8.87 | -12.47 | -16.25 | -19.54 | -36.43 |
| EPS Diluted | -14.20 | -19.96 | -26.01 | -31.26 | -58.29 |
| Normalized Diluted EPS | -8.87 | -12.47 | -16.25 | -19.54 | -36.43 |
| Average Basic Shares Outstanding | 6.11M | 3.00M | 1.65M | 1.16M | 778.10K |
| Average Diluted Shares Outstanding | 6.11M | 3.00M | 1.65M | 1.16M | 778.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |